vialroom

#tirzepatide 2026-03-04

Wednesday29 messages9 participantstimes are UTC
Highlights from this day
  • blind_submit — follow up did anyone find the GI easier than semaglutide at an equivalent effect 09:17
  • gradient_greg — the two compounds arent interchangeable week for week even if the effect ends up similar 09:19
  • nhs_pathway_nell — does the GIP arm actually explain the easier nausea or is that hand waving 09:21
CF

the trials titrated every four weeks to a target, most people here stop at whatever works

CF

at 15 the GI came back for me, so my easier profile claim only applies below that

40 units of a 8 solution is a lot of volume and i check that one twice every single time

07:03quiet.hours pinned a message
DD

the sweet spot thing is survivorship, the people it worked for stayed and said so

DD

i sat at 7.5 for 19 months and never needed more, which is where the folklore comes from

DD

i argued the sweet spot was nonsense and then spent 18 months at 7.5 not needing more

QH

switched from 2.4 semaglutide and started at 2.5, took the slow route, never regretted it

DD

licensed top is 15 weekly, past that is not a licensed dose and nobody here can tell you what it does

QH

changed my mind about needing 15, i was chasing a number rather than an outcome

QH

SURMOUNT was the weight programme and SURPASS was diabetes, thats the split people mix up

is there a reason to titrate slower than the four week schedule

VB

Channel stats, last 30 days: 109 messages from 40 members.

BS

im at 1 and thinking about 15, did anyone gain anything from that step

no clean conversion

10 was enough

start low anyway

BS

my Medutest result on a JEEP vial came in at 99 which is why i keep buying from them

follow up did anyone find the GI easier than semaglutide at an equivalent effect

🤝13
FF

i went to 15 and came back to 10, more suppression wasnt more useful for me

NP

does the GIP arm actually explain the easier nausea or is that hand waving

Cited study
Tirzepatide for Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)
New England Journal of Medicine · 2024
AHI as the primary endpoint, with and without PAP therapy.